As of Jul 2022 · from Reg CF Offering (2022) · pre-money + amount raised, not a traded price
Total raised
$348,408
Crowd $41K · Private $308K · 2 rounds since 2021
Latest share price
$2.00
Reg CF · Common Stock · Jan 2022 offering price
Financials
FY2019–FY2021 · from SEC filings · hover any figure for its source
$0
−$201K
2019
$0
$102K
2020
$0
$89K
2021
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2019 reviewed
FY2020 reviewed
FY2021 reviewed
Income statement
Revenue
$0
$0
$0
Cost of goods sold
$0
$0
$0
Net income
-$201,257
$101,611
$89,253
Taxes paid
$0
$0
$0
Balance sheet
Cash
$48,743
$3,693
$12,260
Accounts receivable
$0
$0
$0
Total assets
$48,743
$5,017
$14,324
Short-term debt
$0
$0
$2,552
Long-term debt
$0
$0
$10,210
Total liabilities
$0
$0
$12,762
Other
Headcount
—
4
4
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came in
$26.7M
pre-money
Reg CF · Common · Jan 2022
Blue bars are the pre-money valuation the company stated for a priced round.
Share price over rounds
$2.00$1.00$0.7035
Dec 2021Jan 2022
Round offering price or verified disclosed saleDisclosed sale, unverified or year-only
Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.
Founder of BREATHE e-cigarette vaporizer Corporation (OTCQB BVAP,) and former CEO & President of 4M leading the commercialization of plasma oxidation for the production of carbon fiber at scale.
Ken GreenwoodFounder
Chief Technology Officer
30 years SAP enterprise-scale implementations, ABAP, OO, SQL, XML, HTML et al, application performance, security, BI/BW big data, analytics and startup experience.
Mike AgentisFounder
Chief Operating Officer
Business strategy, contract and project management, operation management, cost controls.
Igor Gonda
Chief Scientist
Former CEO of Aradigm Corporation. Lead strategic business alliances with major pharmaceutical and biotechnology companies. Research and development of products for major pharmaceutical markets such as diabetes and pain management.
Jurgen Volrath
Chief Intellectual Property Officer
Former CIPO at SAP directly reporting to Hasso Plattner; co-founder of Corinthian Ophthalmic having developed and brought a vaporizer to market.
Don Treacy
Clinical Development Manager
PH.D. Analytical Chemistry & CEO of the Magothy Group, inventor holding two patents: a pulsed dose drug delivery system and an antiviral agent.
Garo Artinian
Advisory to Operations
Former CEO & Chairman of Draka Holding NV, a publicly listed company with revenue in excess of 3 billion Euro.
Richard Dapaah
Venture Advisor
Venture Advisor with MBX Capital, a venture capital firm that funds high impact healthcare and life sciences strategy. Prior to MBX Capital, Richard was part of the founding team at Shire Capital Management, a global multi-strategy investment firm.
Former President and COO of DeRoyal Industries. DeRoyal is a global manufacturer of over 3000 medical devices has over 3,000,000 ft under roof in 6 U.S. states and 7 countries. Annual revenue is approaching $1B.
Paresh Chari
Advisor
Former Dura-Line Chairman of the Board & CEO, Advisory board for Wavin (Netherlands) and Netafim (Israel). Currently advisor to Onward Capital.
Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Not requiredFewer than 300 holders of record
Filed 1 of 5 annual reports (FY2021–FY2025)
81 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.
